Psychological distress as a host-state factor in cancer immunotherapy: clinical associations, neuroendocrine mechanisms, and future trial design
- 1Department of Anesthesiology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University
- 2Department of Thoracic Surgery, the Third Affiliated Hospital of Chongqing Medical University
Abstract
Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have transformed the treatment of multiple solid tumours, yet durable benefit remains confined to a subset of patients. Tumour-intrinsic biomarkers explain only part of this variability, highlighting the need to consider host-level determinants of antitumour immunity. Psychological distress, including depressive and anxiety symptoms, is common in patients with cancer and is potentially modifiable. In this review, we appraise clinical evidence linking pretreatment distress with ICI outcomes, with the principal clinical evidence coming from the prospective STRESS-LUNG cohort, the PRADO melanoma post-hoc analysis, and an individual patient-data meta-analysis of atezolizumab trials. Collectively, the available clinical evidence more strongly supports a general prognostic association, while an ICI-specific predictive effect has not been demonstrated. We then examine mechanistic evidence linking experimental chronic stress and stress-responsive signalling to sympathetic β-adrenergic and hypothalamic–pituitary–adrenal-axis pathways. These pathways can affect CD8 ⁺ T cells, dendritic cells, tumour cells, and the tumour microenvironment in preclinical and translational models. We also discuss psychosocial intervention, β-adrenergic blockade, and serotonergic modulation. For each approach, clinical evidence remains more limited than the mechanistic rationale. Existing evidence supports psychological distress as a clinically important and potentially modifiable host factor associated with inferior outcomes after checkpoint blockade, but does not establish that distress reduction improves ICI efficacy. Randomized, biomarker-informed studies are needed to determine whether modifying distress-related pathways can alter ICI outcomes, rather than simply identify patients with poorer prognosis.
Related
- Prospective associations between perceived school climate and psychological distress among Chinese adolescents: a three-wave longitudinal study of school belonging, social avoidance, and psychological resilience
- Nonlinear associations between physical activity, sleep quality, and psychological distress in university students: a cross-sectional interpretable machine learning study
- Patient-Reported Dysphagia After Multimodal Therapy and Radial Forearm Free-Flap Reconstruction for OPSCC: Associations With FEES Findings, Psychological Distress, and Xerostomia.
- Self-compassion, psychological distress, and mental well-being in a predominantly young student sample: Cross-sectional associations and continuous interaction analysis
- Perceived academic demands and psychological distress among Chinese university students: structural associations involving chronic time pressure and leisure-time physical activity.
BibTeX
@article{lin2026psychological,
title = {{Psychological distress as a host-state factor in cancer immunotherapy: clinical associations, neuroendocrine mechanisms, and future trial design}},
author = {Guanwen Lin and Zhilin Luo},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1899935},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1899935/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Psychological distress as a host-state factor in cancer immunotherapy: clinical associations, neuroendocrine mechanisms, and future trial design
AU - Guanwen Lin
AU - Zhilin Luo
PY - 2026
DA - 2026/10/28
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1899935
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1899935/full
AB - Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have transformed the treatment of multiple solid tumours, yet durable benefit remains confined to a subset of patients. Tumour-intrinsic biomarkers explain only part of this variability, highlighting the need to consider host-level determinants of antitumour immunity. Psychological distress, including depressive and anxiety symptoms, is common in patients with cancer and is potentially modifiable. In this review, we appraise clinical evidence linking pretreatment distress with ICI outcomes, with the principal clinical evidence coming from the prospective STRESS-LUNG cohort, the PRADO melanoma post-hoc analysis, and an individual patient-data meta-analysis of atezolizumab trials. Collectively, the available clinical evidence more strongly supports a general prognostic association, while an ICI-specific predictive effect has not been demonstrated. We then examine mechanistic evidence linking experimental chronic stress and stress-responsive signalling to sympathetic β-adrenergic and hypothalamic–pituitary–adrenal-axis pathways. These pathways can affect CD8 ⁺ T cells, dendritic cells, tumour cells, and the tumour microenvironment in preclinical and translational models. We also discuss psychosocial intervention, β-adrenergic blockade, and serotonergic modulation. For each approach, clinical evidence remains more limited than the mechanistic rationale. Existing evidence supports psychological distress as a clinically important and potentially modifiable host factor associated with inferior outcomes after checkpoint blockade, but does not establish that distress reduction improves ICI efficacy. Randomized, biomarker-informed studies are needed to determine whether modifying distress-related pathways can alter ICI outcomes, rather than simply identify patients with poorer prognosis.
SN - 2234-943X
ER -